QINLOCK 50 mg, tablet 90 tablets
Active ingredients: RIPRÉTINIB
Commercialized according to BDPMDispensing in France: Prescription only
Tablet90 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- QINLOCK 50 mg, comprimé
- Pharmaceutical form
- comprimé
- Route of administration
- orale
- Presentation description
- 1 flacon(s) polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 90 comprimé(s)
- Marketing authorisation holder
- DECIPHERA PHARMACEUTICALS (NETHERLANDS) (PAYS-BAS)
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 11 Apr 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
67629484CIP73024364CIP133400930243640Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| RIPRÉTINIBcomprimé | 50 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.